Cannella, L. et al. 2010. Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months. Acta Oncologica. 49, 3 (Jan. 2010), 399–400. DOI:https://doi.org/10.3109/02841860903521129.